LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 211,600 shares, a drop of 34.3% from the March 15th total of 322,100 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 1,750,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Thursday, March 21st.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX traded down $0.21 during trading hours on Friday, hitting $3.13. 150,913 shares of the company traded hands, compared to its average volume of 1,616,565. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.62 and a quick ratio of 6.62. The firm’s 50-day simple moving average is $2.62 and its 200-day simple moving average is $1.89. LAVA Therapeutics has a one year low of $1.13 and a one year high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.40). LAVA Therapeutics had a negative net margin of 620.09% and a negative return on equity of 68.54%. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $25.00 million. As a group, equities research analysts predict that LAVA Therapeutics will post -1.41 EPS for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

Several large investors have recently bought and sold shares of the stock. Pathway Financial Advisors LLC bought a new stake in shares of LAVA Therapeutics during the 1st quarter worth $47,000. Renaissance Technologies LLC purchased a new position in LAVA Therapeutics during the 4th quarter valued at about $66,000. Citadel Advisors LLC purchased a new position in LAVA Therapeutics during the 4th quarter valued at about $34,000. Bank of America Corp DE grew its holdings in LAVA Therapeutics by 20,566.7% during the 1st quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock valued at $54,000 after buying an additional 32,084 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of LAVA Therapeutics by 30.0% during the second quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock worth $132,000 after purchasing an additional 15,000 shares in the last quarter.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.